Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More

Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.

Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer

The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.

The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric

The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric

Kinjel Shah headshot

Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug

Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Merck & Honeywell

Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola Company (KO), Merck (MRK) and Honeywell International (HON).

Model N (MODN) Q4 Earnings Beat, Stock Down on Bleak View

Model N's (MODN) fourth-quarter fiscal 2020 results benefit from robust adoption of Revenue Cloud platform and strong sales execution. However, bleak guidance for fiscal 2021 remains a concern.

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study

Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.

Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss

Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat

Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.

Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.

Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.

AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat

AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.

Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.

Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger

Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.

Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances

Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.

Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut

Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

Sanghamitra Saha headshot

Worried About Dow's Massive Crash? ETF & Stocks to Play

Rising fears of a second wave of lockdown globally sent Wall Street crashing on Wednesday with the Dow Jones being one of the worst hurt.

Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

Wall Street Opens Green on Strong Economic Data

Wall Street Opens Green on Strong Economic Data.